Dr Agarwals Eye Hospital Ltd

Dr Agarwal’s Eye Hospital Limited – Trading Window closed from September 30, 2026; reopens 48 hours after the announcement of Unaudited Financial Results for the quarter and half year ending September 30, 2026.

AGM Details

• Date and mode: Sep 9, 2026 at 10:30 AM via VC/OAVM.
• Cut-off date for voting: Sep 2, 2026.
• Shareholders on record: 22,056.

Resolutions

• Adopt Audited Financial Statements for FY ended Mar 31, 2026; ordinary; passed.
• Declare dividend of Rs 4 per equity share; ordinary; passed.
• Re-appoint Dr. Adil Agarwal as director by rotation; ordinary; passed.
• Ratify remuneration of Cost Auditor for 2025-26; ordinary; passed.
• Approve revision in remuneration of Dr. Amar Agarwal, Chairman cum MD; special; passed.
• Approve revision in remuneration of Dr. Athiya Agarwal, Whole-Time Director; special; passed.

AGM details

• AGM held on 09 September 2026 at 10:30 AM IST via VC/OAVM.

Resolutions

• Adoption of audited financial statements for FY ended 31 March 2026 (Ordinary).
• Dividend on equity shares declared for FY 2025-26 (Ordinary).
• Appointment of Dr. Adil Agarwal, retires by rotation, for reappointment (Ordinary).
• Ratification of remuneration to Cost Auditor for FY 2025-26 (Ordinary).
• Revision in remuneration of Dr. Amar Agarwal, Chairman cum MD (Special).
• Revision in remuneration of Dr. Athiya Agarwal, Whole-time Director (Special).

Voting results

• All six resolutions passed with requisite majority.

Dividend detail

• Dividend declared on equity shares for FY 2025-26.

Directors

• Dr. Adil Agarwal reappointed by rotation.

Auditors

• Remuneration of Cost Auditor for FY 2025-26 ratified.

Centre launch details

• Launched dedicated Pinhole Pupilloplasty Centre at the Chennai flagship facility.
• Inaugurated on August 27, 2026 by Tamil Nadu Chief Minister Thiru C. Joseph Vijay.
• Centre focuses on PPP technique for complex corneal disorders.
• PPP enables tissue-preserving treatment, reducing donor cornea reliance.
• PPP has provided vision to over 5,000 patients to date.
• Centre will provide diagnostics, surgery, training and long-term follow-up.
• More than 50 ophthalmologists trained annually through workshops.
• Launch aligns with the 41st National Eye Donation Fortnight.
• Centre complements community eye-health initiatives in Tamil Nadu.
• No donor tissue required for PPP.

AGM Details

• 32nd AGM on September 9, 2026 at 10:30 AM IST via VC/OAVM.
• Record date for dividend entitlements: September 2, 2026.
• Dividend subject to approval; Board recommended final dividend.
• AGM conducted through VC/OAVM per MCA circulars.

Key Resolutions

• Adoption of audited financial statements for year ended March 31, 2026.
• Re-appointment of Dr. Adil Agarwal as Director (retiring by rotation).
• Ratification of cost auditor remuneration for 2025-26.

Dividend

• Final dividend proposed: ₹4.00 per share (40%), subject to approval.
• Dividend payable by Oct 8, 2026 to registered members.

Remuneration approvals

• Special Resolution: Amar Agarwal remuneration revised; fixed salary INR 3.40 crore; commission up to INR 1.6 crore.
• Special Resolution: Athiya Agarwal remuneration revised; fixed salary INR 1.35 crore; perquisites as policy.

Financial highlights

• Total income for FY26: INR 476.69 crores, up 18.5% YoY.
• Revenue from operations: INR 470.87 crores.
• EBITDA: INR 151.13 crores; margin 32.0%.
• PAT: INR 70.10 crores; EPS: INR 147.02.
• Total comprehensive income: INR 70.12 crores.

Operations & network

• Network expanded to 63 facilities in India, from 61.
• Mature centers generating cash to fund growth.
• Merger with AHCL approved; NCLT sanction pending.
• Strategic expansion in Tamil Nadu and underserved markets.

Capital structure & funding

• Equity share capital rose to INR 4.83 crores after preferential issue.
• Funds raised via preferential issue: INR 70 crores.
• Total borrowings: INR 326.13 crores; lease liabilities: INR 244.32 crores.
• Net debt: INR 319.42 crores; Debt/Equity: 0.92x.
• Undrawn bank facilities: INR 4.0 crores.
• Capital work-in-progress: INR 197.32 crores; completion expected Sep 2026.
• Shares issued: 132,827 via preferential issue.

Dividends

• Interim dividend: INR 3 per share; final dividend proposed: INR 4 per share.
• Final dividend payable within 30 days of AGM.
• Total dividend per share for FY26: INR 7.

Governance & audits

• Statutory auditors: S.R. Batliboi & Associates LLP; audit is unqualified.
• Secretarial audit: no observations; Scrutinizer: Subramanian Chandrasekar.
• Board: six directors; mix of executives, independent, and one woman.
• Independent directors met Feb 16, 2026 for performance review.

Strategic developments

• Scheme of amalgamation with AHCL approved; awaiting NCLT sanction.
• NSE admission to trading under DRAGARWQ; listing formalities underway.
• NCLT directed meetings for scheme approval on July 2, 2026.
• Focus on Tamil Nadu expansion and disciplined capex.

CSR & ESG

• CSR expenditure ₹1.25 crore; 2% average net profit target ₹1.20 crore.
• Eight CSR thrust areas; emphasis on education and healthcare.
• CSR policy and projects disclosed on the company website.

Risks & outlook

• No material post-year changes; risk management ongoing.
• Potential regulatory approvals and integration synergies from AHCL merger.

Acquisition details

• Target: Dr Agarwal's Health Care Limited.
• Acquirer and PACs: Invesco Mutual Fund; six listed schemes.
• Promoter/promoter group: No.
• Exchanges: BSE Limited and National Stock Exchange of India Limited.
• Pre-acquisition voting-rights: 95,86,950 shares (3.0240%).
• Pre-acquisition encumbrance: Nil.
• Acquisition: 69,38,186 voting-rights shares acquired (2.1885%).
• Encumbrance on acquisition: Nil.
• Post-acquisition voting-rights: 1,65,25,136 shares (5.2125%).
• Mode of acquisition: Open Market.
• Date of acquisition: Aug 12, 2026.
• Equity capital before: Rs 31,70,26,183.
• Equity capital after: Rs 31,70,26,183.
• Total diluted capital after: NA.
• Salient features: NA.

Meeting Details

• Board meeting scheduled for Monday, August 03, 2026 (time and venue not disclosed).

Key Agenda Items

• Consider and approve the unaudited financial results for the quarter ended June 30, 2026.

Other Notes

• Trading window closed until 48 hours after the results announcement.